The Boston University Clinical and Translational Science Institute (BU CTSI) is comprised of the BU Medical Campus (applicant), BU Charles River Campus, Boston Medical Center with its 15 Community Health Centers and Roger Williams Medical Center, in Providence, Rhode Island, along with partnerships with the Boston VAMC and Edith Norse Rogers Memorial Veterans Hospital. The Institute's vision centers on process improvement in providing resources and services, on game-changing disruptive innovations and on competency based team science education. Three highly interactive institute aims help create the most efficient system for clinical and translational research, develop creative scientific tools to expedite and retool traditional research processes, and train future translational scientists to do it. We will: 1) Create an Integrated Home for translational science that: A. integrates a pilot award program to target gaps in drug and device development;B. has a highly secure HIPAA compliant NIST-approved environment for data;C. contains efficiency measures for human subjects research;and D. incorporates new evaluation tools that assess processes and costs to be responsive to new opportunities and strategies. 2) Create an efficient delivery of Clinical and Translational Research Services to implement solutions that streamline and improve the quality, safety, efficiency and cost of clinical research. These include: A. skilld research personnel;B. an EMR-based Registry of ethnic populations;C. faster regulatory approval;D. consultative services for study design, biostatistics and bioinformatics;E. biobanking blood from our Registry for creation of iPS cells from normal subjects for drug toxicity screening;and F. creative tools to expedite and retool traditional research. 3) Create a Career Development Program for Future Scientists that: A. has a competency-based curriculum and evaluation approaches;B. supports a KL2 mentor based program in translational science;C. launches a new TL1 Program for supporting PhD scholars in translational science focused on regenerative medicine;D. provides mentor skill building tools to sustain high quality research mentoring;E. creates online self-directed modularized courses to enhance knowledge in informatics and other key translational research topics;F. implements an education evaluation plan and G. helps scientists with the downstream phase of commercialization of research. These associations and aims will support the mission of NCATS to change and speed the planning and implementation of clinical and translational research.

Public Health Relevance

Through an integrated home that builds upon institutional strengths, the mission of the BU CTSI is to catalyze the generation of innovative processes, methods and techniques that will enhance and speed the development, testing, and implementation of devices, diagnostics and therapeutics, across a wide range of human diseases and conditions. This will accelerate discoveries to improve the public health.

Agency
National Institute of Health (NIH)
Institute
National Center for Advancing Translational Sciences (NCATS)
Type
Specialized Center--Cooperative Agreements (U54)
Project #
1U54TR001012-01
Application #
8603963
Study Section
Special Emphasis Panel (ZAI1-PTM-C (S2))
Program Officer
Rosenblum, Daniel
Project Start
2014-08-20
Project End
2015-08-19
Budget Start
2014-08-20
Budget End
2015-08-19
Support Year
1
Fiscal Year
2014
Total Cost
$3,767,904
Indirect Cost
$1,286,846
Name
Boston University
Department
Type
Organized Research Units
DUNS #
604483045
City
Boston
State
MA
Country
United States
Zip Code
02118
Alshenibr, Weam; Tashkandi, Mustafa M; Alsaqer, Saqer F et al. (2017) Anabolic role of lysyl oxidase like-2 in cartilage of knee and temporomandibular joints with osteoarthritis. Arthritis Res Ther 19:179
Arvanitis, Marios; Koch, Clarissa M; Chan, Gloria G et al. (2017) Identification of Transthyretin Cardiac Amyloidosis Using Serum Retinol-Binding Protein 4 and a Clinical Prediction Model. JAMA Cardiol 2:305-313
Ko, Darae; Thigpen, Jonathan L; Otis, James A et al. (2017) Influence of statin therapy at time of stroke onset on functional outcome among patients with atrial fibrillation. Int J Cardiol 227:808-812
Medrano, Jose L; Naya, Francisco J (2017) The transcription factor MEF2A fine-tunes gene expression in the atrial and ventricular chambers of the adult heart. J Biol Chem 292:20975-20988
Alsaqer, Saqer F; Tashkandi, Mustafa M; Kartha, Vinay K et al. (2017) Inhibition of LSD1 epigenetically attenuates oral cancer growth and metastasis. Oncotarget 8:73372-73386
Chen, Andy; Wang, Luqi; Li, Bai-Yan et al. (2017) Reduction in Migratory Phenotype in a Metastasized Breast Cancer Cell Line via Downregulation of S100A4 and GRM3. Sci Rep 7:3459
Arvanitis, Marios; Simon, Steven; Chan, Gloria et al. (2017) Retinol binding protein 4 (RBP4) concentration identifies V122I transthyretin cardiac amyloidosis. Amyloid 24:120-121
Sussan, Thomas E; Sudini, Kuladeep; Talbot Jr, C Conover et al. (2017) Nrf2 regulates gene-environment interactions in an animal model of intrauterine inflammation: Implications for preterm birth and prematurity. Sci Rep 7:40194
Arvanitis, Marios; Chan, Gloria G; Jacobson, Daniel R et al. (2017) Prevalence of mutant ATTR cardiac amyloidosis in elderly African Americans with heart failure. Amyloid 24:253-255
Desjardins, Cody A; Naya, Francisco J (2017) Antagonistic regulation of cell-cycle and differentiation gene programs in neonatal cardiomyocytes by homologous MEF2 transcription factors. J Biol Chem 292:10613-10629

Showing the most recent 10 out of 30 publications